Transforming Rare Polyphenols into Botanical Drugs
Canurta Therapeutics is at the forefront of developing multi-target botanical drugs, utilizing rare polyphenols to offer innovative treatments for inflammation and neurological diseases.
Our proprietary manufacturing processes and AI-driven bioinformatics enable us to transform polyphenols like cannflavins A and B into high-quality, clinically active biopharmaceutical ingredients. Our approach provides safe, effective treatments for some of the most complex and challenging diseases.
Our Approach to Complex Disease
Neurological and inflammatory diseases, like Amyotrophic Lateral Sclerosis (ALS), are driven by a web of interconnected biological pathways, making them difficult to treat with single-target therapies. At Canurta, we believe the future lies in a multi-target approach. Our research into bioactive compounds reveals their ability to interact with multiple systems—modulating processes like inflammation, oxidative stress, and cell survival.
Our multi-target approach is crucial for treating complex diseases. Our lead candidate, CNR-401 embodies this strategy by targeting multiple key mechanisms involved in ALS, offering a comprehensive solution to combat the disease. While current treatments offer limited neuroprotection and symptom relief, Canurta’s botanical therapies aim to slow disease progression, relieve symptoms, and enhance quality of life. By optimizing combinations of bioactive compounds, our pipeline has the potential to deliver consistent therapeutic benefits across ALS and a broader range of neurodegenerative and inflammatory diseases.
Harnessing Nature’s Rarest Polyphenols
Polyphenols are a diverse group of naturally occurring compounds widely found in plants, recognized for their broad therapeutic benefits.
Notably, cannflavins A & B are rare, multipotent polyphenols with powerful anti-inflammatory and neuroprotective properties. Preclinical studies show they are 30 times more effective than nonsteroidal anti-inflammatory drugs (NSAIDs) in reducing inflammation, offering a safer alternative with minimal side effects.
Canurta’s proprietary technology enriches and enhances these non-psychoactive compounds, maximizing their bioavailability and potential for clinical and commercial use.
Utilizing Technology for Enhanced Drug Development
Canurta’s PolyKye™ platform accelerates drug discovery by integrating AI and bioinformatics to discover, optimize, and predict the therapeutic potential of bioactive compounds like cannflavins.
By refining known and new molecules and tailoring treatments with precision medicine modeling, we ensure faster development and market readiness. While our blockchain-enabled supply chain guarantees Chemistry, Manufacturing, and Controls (CMC) compliance and transparency, setting new standards for efficiency in botanical therapeutics.
Next Generation
Multi-Target Therapeutics
Through strategic collaborations and cutting-edge research, Canurta is transforming preclinical discoveries into real-world therapies.
With a focus on novel polyphenols, we are advancing multi-target solutions for neurodegenerative and inflammatory diseases, bringing new hope to patients where conventional treatments fall short.
